Mateusz D. Tomczyk

Mar 10, 2024 | nature.com | Mahmoud Ahmed |Nicholas T. Lam |Ivan Menendez-Montes |Ilaria Secco |Mateusz D. Tomczyk |Diana R. Tomchick | +4 more

AbstractTargeting Meis1 and Hoxb13 transcriptional activity could be a viable therapeutic strategy for heart regeneration. In this study, we performd an in silico screening to identify FDA-approved drugs that can inhibit Meis1 and Hoxb13 transcriptional activity based on the resolved crystal structure of Meis1 and Hoxb13 bound to DNA.